DK1957528T3 - Nukleotid-vaccine - Google Patents

Nukleotid-vaccine

Info

Publication number
DK1957528T3
DK1957528T3 DK06818135.3T DK06818135T DK1957528T3 DK 1957528 T3 DK1957528 T3 DK 1957528T3 DK 06818135 T DK06818135 T DK 06818135T DK 1957528 T3 DK1957528 T3 DK 1957528T3
Authority
DK
Denmark
Prior art keywords
nucleotide vaccine
vaccine
nucleotide
Prior art date
Application number
DK06818135.3T
Other languages
English (en)
Inventor
Peter Johannes Holst
Allan Randrup Thomsen
Jan Pravsgaard Christensen
Original Assignee
Univ Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Copenhagen filed Critical Univ Copenhagen
Application granted granted Critical
Publication of DK1957528T3 publication Critical patent/DK1957528T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK06818135.3T 2005-11-30 2006-11-30 Nukleotid-vaccine DK1957528T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200501697 2005-11-30
US75571205P 2005-12-30 2005-12-30
DKPA200501857 2005-12-30
DKPA200600431 2006-03-27
PCT/DK2006/000675 WO2007062656A2 (en) 2005-11-30 2006-11-30 A nucleotide vaccine

Publications (1)

Publication Number Publication Date
DK1957528T3 true DK1957528T3 (da) 2012-12-17

Family

ID=43030525

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06818135.3T DK1957528T3 (da) 2005-11-30 2006-11-30 Nukleotid-vaccine

Country Status (10)

Country Link
US (3) US20100278904A1 (da)
EP (1) EP1957528B1 (da)
CN (2) CN101321781B (da)
DK (1) DK1957528T3 (da)
ES (1) ES2396437T3 (da)
HK (1) HK1215052A1 (da)
PL (1) PL1957528T3 (da)
PT (1) PT1957528E (da)
SI (1) SI1957528T1 (da)
WO (1) WO2007062656A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014702A2 (en) * 2007-07-25 2009-01-29 Board Of Regents, The University Of Texas System Cd74 for use in the treatment of cancer and liver toxicity
BRPI0921927B8 (pt) * 2008-11-21 2021-08-31 Koebenhavns Univ University Of Copenhagen Sensibilização de uma resposta imune
AU2015227479B2 (en) * 2008-11-21 2017-05-04 Københavns Universitet (University Of Copenhagen) Priming of an immune response
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
WO2011114346A1 (en) 2010-03-18 2011-09-22 Chetan Balar Chitin and related compounds for use in treating bacterial and viral infections
CN101991863B (zh) * 2010-04-28 2012-11-07 中国人民解放军军事医学科学院野战输血研究所 一种双重靶向dna疫苗及其构建方法
CN104350070A (zh) * 2012-01-27 2015-02-11 生物防护科技公司 调节免疫反应的组合物和方法
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
CN103819562B (zh) * 2013-06-03 2017-02-08 安徽农业大学 一种基于鸡恒定链片段的疫苗载体的构建与应用
CN103966219B (zh) * 2014-05-26 2016-08-10 武汉大学 人泡沫病毒载体介导的抑制HIV-1复制的shRNA的构建及应用
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
CN104306995B (zh) * 2014-10-29 2017-04-12 山东农业大学 一种抗j亚群禽白血病病毒感染的表位疫苗及其制备方法和应用
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CN106511991B (zh) * 2016-12-12 2019-11-08 南京农业大学 Ii基因序列在猪流行性腹泻病毒基因疫苗中的应用
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
IL271965B2 (en) * 2017-07-12 2023-03-01 Nouscom Ag Preparations containing a neoantigenic vaccine for the treatment of cancer
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
US20210008195A1 (en) * 2017-12-20 2021-01-14 Zoetis Services Llc Vaccines against hendra and nipah virus infection
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
WO2020033876A1 (en) 2018-08-10 2020-02-13 Nantbio, Inc. Cellular adjuvants for viral infection
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
RU2725493C2 (ru) * 2018-12-28 2020-07-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
US20230310585A1 (en) * 2020-09-11 2023-10-05 The University Of British Columbia Vaccine for viral pathogens
CN112430625B (zh) * 2020-11-23 2022-08-05 武汉枢密脑科学技术有限公司 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用
AU2022233021A1 (en) * 2021-03-12 2023-09-21 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535178T2 (de) * 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
AU7690896A (en) * 1995-09-14 1997-04-01 Universitat Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
US6294378B1 (en) * 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
AU6336398A (en) * 1997-02-24 1998-09-09 Johns Hopkins University, The Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
EP1054856A1 (en) * 1998-02-09 2000-11-29 RPC Inc. Process for treating cobalt catalyst in oxidation mixtures of hydrocarbons to dibasic acids
JP2002520000A (ja) * 1998-05-13 2002-07-09 エピミューン， インコーポレイテッド 免疫応答を刺激するための発現ベクターおよびそのベクターの使用方法
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
PT1385538E (pt) * 2001-04-05 2013-05-07 Univ Johns Hopkins Vacinas quiméricas compreendendo o domínio luminal de lamp-1 ou lamp-2
DE10228218A1 (de) * 2002-06-25 2004-02-05 Norbert Prof. Koch Nukleinsäuren für DNS-Immunisierung zur Antikörperproduktion
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines

Also Published As

Publication number Publication date
CN105039372A (zh) 2015-11-11
EP1957528A2 (en) 2008-08-20
PT1957528E (pt) 2013-01-09
ES2396437T3 (es) 2013-02-21
US20210230633A1 (en) 2021-07-29
US20100278904A1 (en) 2010-11-04
EP1957528B1 (en) 2012-11-07
HK1215052A1 (zh) 2016-08-12
WO2007062656A2 (en) 2007-06-07
CN101321781A (zh) 2008-12-10
WO2007062656A3 (en) 2008-05-22
US20150368672A1 (en) 2015-12-24
SI1957528T1 (sl) 2013-02-28
PL1957528T3 (pl) 2013-03-29
CN101321781B (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
DK1957528T3 (da) Nukleotid-vaccine
DK1968631T3 (da) Vaccine
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE502006003394D1 (de) Lehnenklappung
DE602006012066D1 (de) Daraus
DE502006008475D1 (de) Wasserpumpenflügelrad
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DE502006005667D1 (de) Gelenklager
ATE549324T1 (de) Tetrahydrobenzoxazine
DK1848727T3 (da) Ibandronat polymorf b
DE502006006857D1 (de) Wingungserregern
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DK1907574T3 (da) Oligonukleotider
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502005005839D1 (de) Feldgeerät
DE502006001397D1 (de) Lagerbuchse
DK1877549T3 (da) HIV-vaccine
DE502006004302D1 (de) Verschlusskappe
DE502006001004D1 (de) Hydrolager
DE102005052834B8 (de) Punktschweißklebverbindung
DE502006003210D1 (de) Nohydrogenpolysiloxanen
AT501523A3 (de) Estrich
DE102006033170A8 (de) Einfassnähmaschine
DE502006006199D1 (de) Rzuständen